CABOTEGRAVIR; RILPIVIRINE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888	NDA	ViiV Healthcare Company	49702-240-15	1 KIT in 1 CARTON (49702-240-15) * 3 mL in 1 VIAL (49702-238-01) * 3 mL in 1 VIAL (49702-243-02)	2021-01-21
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888	NDA	ViiV Healthcare Company	49702-253-15	1 KIT in 1 CARTON (49702-253-15) * 2 mL in 1 VIAL (49702-245-01) * 2 mL in 1 VIAL (49702-249-02)	2021-01-21
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888	NDA	ViiV Healthcare Company	49702-266-63	1 KIT in 1 CARTON (49702-266-63) * 3 mL in 1 VIAL (49702-238-64) * 3 mL in 1 VIAL (49702-243-61)	2025-01-21
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the supplier landscape for cabotegravir and rilpivirine, key active pharmaceutical ingredients (APIs) in long-acting injectable HIV treatments. The focus is on identifying key manufacturing entities, their geographic distribution, and the potential impact on supply chain resilience and cost.

Who are the primary manufacturers of cabotegravir and rilpivirine APIs?

The development and manufacturing of cabotegravir and rilpivirine are primarily consolidated with ViiV Healthcare, a joint venture between GSK, Pfizer, and Shionogi. ViiV Healthcare holds the patents and controls the manufacturing processes for these APIs. As such, direct third-party suppliers of the finished APIs to the broader market are limited, with ViiV Healthcare serving as the central entity.

Cabotegravir: ViiV Healthcare, through its manufacturing network and contracted partners, produces cabotegravir. The primary synthesis and formulation stages are managed by ViiV Healthcare.
Rilpivirine: Similarly, rilpivirine production is overseen by ViiV Healthcare. The proprietary manufacturing processes are held by the company.

While ViiV Healthcare is the primary API source, the manufacturing of the drug product (the final injectable formulation, such as Cabenuva) involves multiple steps and potentially other entities. These can include:

Contract Manufacturing Organizations (CMOs): ViiV Healthcare may utilize CMOs for specific stages of API production or for the formulation and filling of the final injectable drug product. These CMOs often operate under strict quality agreements and regulatory oversight from ViiV Healthcare.
Excipient Suppliers: The formulation of long-acting injectables requires specialized excipients that enable the sustained release of the APIs. These excipients are sourced from a broader range of chemical manufacturers. Examples of excipients that are critical for such formulations include polymers like polylactic-co-glycolic acid (PLGA).

What is the geographic concentration of these API manufacturers?

The manufacturing of cabotegravir and rilpivirine APIs, under the purview of ViiV Healthcare, is not solely confined to one geographic region. ViiV Healthcare operates a global supply chain, leveraging its parent companies' (GSK and Pfizer) manufacturing infrastructure and their network of strategic partners.

API Synthesis: While specific plant locations are proprietary, ViiV Healthcare’s API synthesis operations for both cabotegravir and rilpivirine are likely distributed across facilities in North America, Europe, and Asia. This global dispersion is a standard practice to mitigate geopolitical risks, optimize costs, and ensure regulatory compliance in various jurisdictions.
Formulation and Fill-Finish: The final drug product manufacturing, involving the sterile processing and filling of the injectable suspension, is a highly specialized and regulated activity. ViiV Healthcare's own manufacturing sites and selected CMOs with advanced sterile manufacturing capabilities are involved. These facilities are located in regions with robust pharmaceutical manufacturing ecosystems and stringent regulatory oversight, such as the United States, Ireland, and the United Kingdom.

Example of Potential Manufacturing Hubs (based on ViiV Healthcare's broader network and typical industry practices):

United States: Pfizer and GSK have significant manufacturing presence and R&D centers in the US, often involved in API synthesis and drug product manufacturing.
Europe: GSK has major pharmaceutical manufacturing sites in the UK and Ireland, which are highly regulated and capable of complex drug substance and drug product production.
Asia: Singapore and certain regions in China and India are increasingly important hubs for pharmaceutical API manufacturing, and ViiV Healthcare may utilize contracted capacity in these regions for specific intermediates or API production, subject to rigorous quality control.

What are the patent landscapes for cabotegravir and rilpivirine?

The patent landscape for cabotegravir and rilpivirine is complex and forms the basis of ViiV Healthcare's market exclusivity. These patents cover the chemical entities themselves, various crystalline forms, manufacturing processes, and specific formulations, including long-acting injectable compositions.

Cabotegravir Patents

Core Compound Patents: Patents covering the cabotegravir molecule itself are fundamental. These typically have an initial term of 20 years from the filing date, with potential extensions.
Formulation Patents: Patents protecting the specific long-acting injectable formulations are crucial. These patents address the delivery mechanism, excipients, and the resulting pharmacokinetic profiles. For example, patents related to Cabenuva (cabotegravir and rilpivirine injectable suspension) will detail the unique characteristics of the co-formulation and its administration.
Process Patents: Patents may also cover specific synthetic routes or purification methods used to manufacture cabotegravir, potentially offering protection beyond the compound patent expiry.
Polymorph Patents: Patents for specific crystalline forms (polymorphs) of cabotegravir can provide additional layers of protection, as different solid forms can have distinct physical and chemical properties affecting stability and bioavailability.

Key Patent Holders: ViiV Healthcare, along with its parent companies GSK and Pfizer, are the primary patent holders for cabotegravir. Patents are filed and maintained in major pharmaceutical markets globally, including the United States, European Union, Japan, and China.

Rilpivirine Patents

Core Compound Patents: Similar to cabotegravir, initial patents cover the rilpivirine molecule.
Formulation Patents: Patents for the co-formulated injectable product containing rilpivirine are critical for its long-acting application.
Process Patents: Specific manufacturing processes for rilpivirine may be patented.
Polymorph Patents: Patents for different solid forms of rilpivirine can also exist.

Key Patent Holders: Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) was an original developer and patent holder for rilpivirine. However, through licensing agreements and ViiV Healthcare's development of the injectable combination, ViiV Healthcare is the primary entity responsible for the long-acting formulation and its associated intellectual property in this context.

Patent Expiry: The expiry dates of these patents are critical for understanding the timeline for generic competition.

Cabotegravir: Primary patents are expected to begin expiring in the late 2020s and into the 2030s, depending on the specific patent and jurisdiction.
Rilpivirine: The patent expiry for rilpivirine has varied, with some forms and applications facing or approaching generic entry. However, specific patents covering ViiV Healthcare's long-acting injectable formulations will dictate the market exclusivity for that specific product.

Impact of Patent Expiry: Upon patent expiry, the market opens for generic manufacturers to produce and sell biosimilar or generic versions of the drugs, provided they meet regulatory approval standards. This typically leads to significant price reductions. For long-acting injectables, the complexity of formulation and manufacturing processes can create higher barriers to entry for generic competitors compared to oral dosage forms.

What are the regulatory considerations for supplying cabotegravir and rilpivirine?

Supplying APIs for pharmaceutical products like cabotegravir and rilpivirine involves stringent regulatory oversight to ensure product quality, safety, and efficacy. The primary regulatory bodies involved are the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national regulatory authorities in other key markets.

Good Manufacturing Practices (GMP)

API Manufacturing: All facilities involved in the synthesis and purification of cabotegravir and rilpivirine APIs must adhere to Current Good Manufacturing Practices (cGMP) as defined by regulatory authorities. This includes robust quality management systems, detailed documentation, validated processes, and strict control over raw materials, intermediates, and finished APIs.
Drug Product Manufacturing: Facilities performing the formulation, sterile filling, and finishing of the injectable drug product must also comply with cGMP. This is particularly critical for sterile injectables, requiring specialized facilities and processes to prevent microbial contamination.

Drug Master Files (DMFs)

API Suppliers: Manufacturers of cabotegravir and rilpivirine APIs typically submit Drug Master Files (DMFs) to regulatory agencies like the FDA and EMA. A DMF is a confidential submission providing detailed information about the manufacturing process, facilities, quality controls, and stability of the API. ViiV Healthcare, as the drug product sponsor, would reference these DMFs in their regulatory submissions.
Confidentiality: DMFs are confidential documents, and regulatory agencies review them as part of the drug product approval process.

Quality Agreements

Sponsor-Supplier Relationship: ViiV Healthcare maintains rigorous Quality Agreements with its API suppliers and CMOs. These agreements legally bind both parties to specific quality standards, responsibilities, and communication protocols. They cover aspects such as change control, deviation management, complaint handling, and audit rights.

Impurity Control

ICH Guidelines: API manufacturers must control impurities within specified limits, as outlined in International Council for Harmonisation (ICH) guidelines (e.g., ICH Q3A for impurities in new drug substances and ICH Q3C for residual solvents). This requires sophisticated analytical methods for identification, quantification, and monitoring of potential process-related impurities and degradation products.

Supply Chain Security and Traceability

Serialization: Regulatory requirements for serialization are increasingly important. Each unit of the finished drug product needs a unique identifier to track its journey from manufacturing to the patient, helping to prevent counterfeiting and improve recall management.
Supply Chain Audits: ViiV Healthcare conducts regular audits of its suppliers to ensure ongoing compliance with cGMP and quality standards.

Special Considerations for Long-Acting Injectables

Sterility Assurance: The manufacturing of sterile injectable suspensions for cabotegravir and rilpivirine is subject to the highest sterility assurance requirements. This includes aseptic processing, terminal sterilization where applicable, and rigorous environmental monitoring.
Particle Size Control: For injectable suspensions, precise control over API particle size is critical for consistent dissolution rates, injectability, and product performance. Analytical methods to verify particle size distribution (e.g., laser diffraction) are essential.

Impact on Suppliers: Any entity seeking to supply cabotegravir or rilpivirine APIs or perform contract manufacturing for ViiV Healthcare must demonstrate a high level of regulatory compliance and a robust quality system. Qualification and auditing processes are extensive and may take significant time and resources.

What are the market dynamics and competitive landscape?

The market for cabotegravir and rilpivirine is dominated by ViiV Healthcare due to its proprietary intellectual property and established market position, particularly in the long-acting injectable HIV treatment space.

ViiV Healthcare's Dominance

Market Exclusivity: ViiV Healthcare holds exclusive rights for the commercialization of cabotegravir and its combination products (such as Cabenuva, which combines cabotegravir and rilpivirine). This exclusivity is underpinned by patents covering the compounds and their specific formulations.
Product Portfolio: ViiV Healthcare's portfolio includes several long-acting injectable HIV treatments, which have seen increasing uptake as alternatives to daily oral regimens. This includes Cabenuva (cabotegravir/rilpivirine) for HIV-1 treatment and prevention (PrEP).
Integrated Supply Chain: ViiV Healthcare manages its supply chain through internal manufacturing and strategic partnerships with contract manufacturers. This integrated approach allows for control over production costs, quality, and supply reliability.

Generic Competition Outlook

Patent Expiry: The timing of patent expiries for cabotegravir and rilpivirine is the primary driver for potential generic market entry. As noted, core compound patents for cabotegravir are expected to expire in the late 2020s and into the 2030s. Rilpivirine has seen some generic activity for its oral forms, but the long-acting injectable formulation has more complex intellectual property and manufacturing barriers.
Barriers to Entry for Generics: The development of generic long-acting injectable drugs presents significant challenges:
- Formulation Complexity: Replicating the proprietary sustained-release formulation technology requires substantial R&D investment and specialized expertise.
- Manufacturing Technology: Sterile manufacturing of injectable suspensions requires advanced facilities, stringent aseptic processing, and sophisticated quality control systems.
- Regulatory Pathway: Demonstrating bioequivalence for long-acting injectables can be more complex than for oral solid dosage forms.
- Patent Litigation: ViiV Healthcare is likely to vigorously defend its intellectual property, potentially leading to patent litigation with generic entrants.

Indirect Suppliers and Service Providers

While direct API suppliers beyond ViiV Healthcare's controlled network are limited, the broader pharmaceutical supply chain involves numerous entities:

Excipient Manufacturers: Companies that produce critical excipients for long-acting injectable formulations, such as specialized polymers (e.g., PLGA), surfactants, and suspending agents. Examples of such companies include Evonik Industries, Ashland, and DuPont.
Contract Manufacturing Organizations (CMOs): CMOs specializing in sterile injectables and complex drug product manufacturing play a crucial role. Companies like Catalent, Thermo Fisher Scientific (Patheon), and Lonza are examples of CMOs that may be involved in formulation, fill-finish, or packaging services for ViiV Healthcare or its contracted API manufacturers.
Analytical Testing Laboratories: Specialized contract research organizations (CROs) and testing labs provide analytical services for API characterization, quality control, stability testing, and method development, essential for regulatory compliance.

Pricing and Accessibility

High Cost of Innovation: Long-acting injectables represent a significant R&D investment and are often priced higher than oral alternatives due to the advanced technology and manufacturing requirements.
Impact of Generics: The introduction of generic versions will be critical for improving affordability and accessibility, particularly in lower and middle-income countries. However, the timeline for this to occur for the long-acting injectable formulations remains dependent on patent expiry and the ability of generic manufacturers to overcome technical and regulatory hurdles.

Key Trends:

Increasing demand for long-acting HIV therapies due to improved patient adherence and convenience.
Strategic partnerships between pharmaceutical innovators and specialized CMOs for complex drug product manufacturing.
Global efforts to expand access to advanced HIV treatments, influencing pricing and supply strategies.

Key Takeaways

ViiV Healthcare is the primary holder of intellectual property and controller of the supply chain for cabotegravir and rilpivirine APIs and their long-acting injectable formulations.
Direct third-party API suppliers to the open market are limited; ViiV Healthcare manages production through its own facilities and contracted CMOs.
Manufacturing is globally distributed but subject to rigorous cGMP and regulatory oversight.
Patent expiry dates are critical for predicting the entry of generic competition, with significant barriers for long-acting injectable formulations.
The market dynamics are characterized by ViiV Healthcare's strong proprietary position, with a gradual outlook for generic market entry due to manufacturing and formulation complexities.

Frequently Asked Questions

Can other companies manufacture cabotegravir or rilpivirine APIs independently of ViiV Healthcare? Currently, independent manufacturing and sale of cabotegravir and rilpivirine APIs are significantly restricted by ViiV Healthcare's patent portfolio covering the active compounds and their production processes. Generic manufacturers can only enter the market after these patents expire, and they successfully navigate regulatory approval and potential patent challenges.
What are the main challenges for generic manufacturers entering the long-acting injectable market for these drugs? Key challenges include replicating the complex sustained-release formulation technology, establishing sterile manufacturing capabilities that meet stringent cGMP standards for injectables, demonstrating bioequivalence, and overcoming potential patent litigation from the innovator.
Who are the critical excipient suppliers for long-acting injectable HIV drugs like Cabenuva? Critical excipient suppliers include manufacturers of specialized polymers like polylactic-co-glycolic acid (PLGA), which are essential for controlled drug release. Leading global chemical companies with expertise in pharmaceutical polymers are potential suppliers.
How does ViiV Healthcare ensure the quality and reliability of its API supply chain? ViiV Healthcare ensures supply chain quality and reliability through rigorous selection and auditing of its manufacturing partners, implementation of stringent Quality Agreements, adherence to global cGMP standards, and robust internal quality management systems.
When can we expect to see generic versions of ViiV Healthcare's long-acting injectable HIV treatments on the market? Generic entry for ViiV Healthcare's long-acting injectable treatments will depend on the expiry of patents specific to these formulations and manufacturing processes. While some compound patents may expire in the late 2020s, the complex nature of the injectable formulation suggests a later timeline, potentially into the 2030s, for significant generic market penetration.

Citations

[1] ViiV Healthcare. (n.d.). Our Products. Retrieved from [ViiV Healthcare's official website - specific product pages for Cabenuva and relevant information on HIV treatments]. (Note: Direct link is not provided as website structures can change, but can be found via a search on ViiV Healthcare's product portfolio.)

[2] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA website on Drug Master Files]. (Note: Specific section on DMFs can be found by searching the FDA's official website.)

[3] European Medicines Agency. (n.d.). Guidance documents. Retrieved from [EMA website, focusing on GMP and quality guidance]. (Note: Specific guidance documents can be found by searching the EMA's website for relevant quality and manufacturing guidelines.)

[4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH website for harmonized guidelines]. (Note: Specific guidelines like ICH Q3A and Q3C are available on the ICH website.)

Suppliers and packagers for generic pharmaceutical drug: CABOTEGRAVIR; RILPIVIRINE